Lurbinectedin Sensitizes PD-L1 Blockade Therapy by Activating STING-IFN Signaling in Small-Cell Lung Cancer

Scientists demonstrated that lurbinectedin treatment activated the STING pathway, which increased interferon (IFN) signaling, pro-inflammatory chemokines, and major histocompatibility complex class I in small-cell lung cancer models.